“I think the take home message of this study is that there's work to do, and that our efforts in diversity, equity, and inclusion extends broadly beyond simply ensuring that we have the workforce to treat our diverse population, or that urologists are thinking critically and responsibly about the needs of our patients,” says Kevin Koo, MD, MPH.
In this video, Kevin Koo, MD, MPH, shares the take-home message from the study, “Disparities in race and ethnicity reporting in contemporary clinical trials leading to new drug approvals in urology,” which was presented at the North Central Section of the American Urological Association Annual Meeting in Chicago, Illinois. Koo is a urologist at Mayo Clinic in Rochester, Minnesota.
Plant-based diets linked to lower risk of prostate cancer progression and recurrence
March 7th 2023"These findings may directly inform clinical care, such as providing diet recommendations for managing health, and potentially offer other positive health benefits for preventing numerous chronic diseases,” said Bradley Alexander McGregor, MD.
Gene therapy EG-70 shows early promise in BCG-unresponsive NMIBC
February 27th 2023"While the data are still early, EG-70's safety profile and efficacy are well on their way towards establishing a new benchmark for monotherapy treatment of high-risk NMIBC with BCG-unresponsive carcinoma in situ,” said lead study author Gary Steinberg MD.
Real-world study investigates first-line avelumab maintenance for metastatic urothelial carcinoma
February 20th 2023Baseline findings showed that patients treated with first-line platinum-based chemotherapy prior to avelumab maintenance experienced a complete response rate of 13% and a partial response rate of 68% to chemotherapy.
2 Clarke Drive
Cranbury, NJ 08512